Actinium Pharmaceuticals announced early positive results from the first-in-human Phase 1 trial of ATNM-400, a novel targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). Unlike existing PSMA-targeted treatments, ATNM-400 targets a different antigen linked to tumor survival and resistance, potentially benefiting patients with PSMA-low or PSMA-negative tumors and those unresponsive to current therapies. The trial evaluates safety, biodistribution, and dosimetry using Zirconium-89-labeled ATNM-400, with findings to guide therapeutic dosing of Actinium-225-labeled ATNM-400. These results mark a significant step forward for treating a broader mCRPC patient population and will be presented at the 2026 European Association of Nuclear Medicine Congress.
Actinium Pharmaceuticals' announcement of early Phase 1 trial results for ATNM-400 provides context for healthcare innovation. For readers following the health sector, here is Pluang's market snapshot as of Oct 15, 2026 18:13 WIB: out of 150 priced US health stocks, 93 rose and 49 fell. Notable movers include ABCL at USD 11.90 with a 1-day change of -3.80% and a typical hold time on Pluang of 41 days, ASND at USD 219.09 down 3.48% with a 56-day hold time, and AXGN at USD 33.97 down 3.33% with a 18-day hold time and Pluang order activity of 61% Buy.
The Saudi Arabia Non-Invasive Prenatal Testing (NIPT) market is projected to grow from $52.5 million in 2025 to $162.16 million by 2034, at a CAGR of 13.35%. Growth is fueled by rising maternal age, advances in molecular diagnostics, and increased he...
TiDB, powered by PingCAP, announced new cloud platform capabilities to support enterprise and AI applications on a unified data foundation. Key updates include the upcoming general availability of TiDB Cloud Premium, public previews of Bring Your Own...
Alcoa will release its Q3 2026 earnings on October 15, with analysts divided on earnings per share and revenue forecasts due to factors like rising aluminum sales, inventory changes, and higher input costs. The company expects a 54.9% jump in aluminu...
Nokia has transferred 2,142,361 of its own shares to employees participating in its stock-based incentive programs, as per a board decision announced in October 2025. This transfer was made without compensation and is part of fulfilling commitments u...
Pallavi Mahajan, a senior manager at Nokia Corporation, received 35,192 shares through a share-based incentive on October 15, 2026. This transaction was reported under EU Market Abuse Regulation, reflecting Nokia's ongoing use of equity incentives to...
